Navigation Links
Uroplasty Announces Patent Issuance Related to the Urgent(R) PC System
Date:7/13/2009

MINNEAPOLIS, July 13 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today the issuance of United States Patent No. 7,536,226 entitled, "Electro-Nerve Stimulator System and Methods." The patent covers the company's Urgent(R) PC system and stimulation methods for treatment of the overactive bladder ("OAB") symptoms of urinary urgency, urge incontinence and frequency of urinary voids.

The Urgent PC Neuromodulation System is a minimally invasive, office-based, nonsurgical system designed to deliver retrograde access to the sacral plexus through percutaneous electrical stimulation of the posterior tibial nerve. The Urgent PC system combines a pulse generator and a lead set to transfer electrical current from the pulse generator to the posterior tibial nerve, and includes a single use feature to prevent reuse of the lead set. By preventing reuse of lead sets, the Urgent PC System eliminates the health risks otherwise associated with re-using the same electrodes.

"We are very pleased that the United States Patent Office has awarded this patent on the unique features of our stimulation systems and methods," said David Kaysen, President and CEO. "This newly issued patent underscores our commitment to protect the unique features of the Urgent PC system. The system's ease of use and treatment effectiveness, coupled with a minimally invasive procedure and single-use features, are seen as key positives by our many clinical users as well as patients treated for the symptoms of OAB."

About the Urgent PC Neuromodulation System

The Urgent PC neuromodulation system is a proprietary, minimally invasive nerve stimulation device designed for office-based treatment of urge incontinence, urinary urgency and urinary frequency, symptoms often associated with overactive bladder. Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to these symptoms.

Uroplasty sells the Urgent PC system in the United States, Canada, and countries recognizing the CE mark. Outside of the United States, Urgent PC is also indicated for the treatment of fecal incontinence.

For more information about the Urgent PC Neuromodulation System, please call 866-277-0466 or visit www.uroplasty.com.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence - symptoms often associated with overactive bladder.

We also offer Macroplastique(R) Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information

This press release contains forward-looking statements, which reflect our best estimates regarding future events and financial performance. Forward-looking statements include statements about the scope of coverage and potential applications for Uroplasty's patents, whether Uroplasty's issued patents will be challenged and whether such challenges will have an adverse effect on the scope of the patents; whether Uroplasty will pursue enforcement of its issued patents or be successful in any such enforcement efforts; whether Uroplasty will successfully prosecute additional patent applications and if so, whether such applications will lead to the issuance of additional patents. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may effect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.


    For Further Information:

    Uroplasty, Inc.                               EVC Group
    ---------------                               ---------
    David Kaysen, President and CEO, or           Doug Sherk (Investors)
    Medi Jiwani, Vice President, CFO, and         415.896.6820
     Treasurer,
    952.426.6140                                  Chris Gale (Media)
                                                  646.201.5431


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results
2. Uroplasty to Issue Fourth Fiscal Quarter and Full Year Results on June 4, 2009
3. Uroplasty to Host Third Fiscal Quarter Conference Call on February 3
4. Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009
5. Uroplasty to Present at the Noble Financial Fourth Annual Equity Conference
6. Uroplasty to Host First Quarter Conference Call on July 31
7. Uroplasty Joins the Russell Microcap Index
8. Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008
9. Uroplasty to Host Fourth Quarter and Year End Conference Call on June 3
10. Uroplasty to Highlight Urgent PC System at American Urological Association 2008 Annual Meeting
11. Uroplasty Plans to Double Sales Force During Fiscal 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into ... claim in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th ... According to the study, medical payments per claim in California decreased 4 percent in ...
(Date:12/8/2016)... ... December 08, 2016 , ... Dickinson Insurance and Financial ... in Little Rock, has initiated a charity drive to provide support and funding ... End Senior Hunger, Arkansas ranks first in senior hunger statewide, third in child ...
(Date:12/8/2016)... ... 08, 2016 , ... Coppin Insurance Agency, an insurance and financial planning firm ... Cape Coral area, is embarking on a charity drive with the goal of providing ... Harry Chapin Food Bank of Southwest Florida works to provide fresh and nutritious food ...
(Date:12/7/2016)... ... 07, 2016 , ... DrugDev again demonstrated its dedication to reducing ... the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of Commerce. ... sides of the Atlantic with a mechanism to comply with EU data protection requirements ...
(Date:12/7/2016)... ... December 07, 2016 , ... Children exposed to secondhand ... at the Icahn School of Medicine at Mount Sinai has found. The study ... young children are exposed to secondhand marijuana smoke, measurable amounts of primary metabolite ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... LITTLE FALLS, N.J., Dec. 8, 2016 CANTEL MEDICAL ... net income of $18,800,000, or $0.45 per diluted share, on ... the first quarter ended October 31, 2016. This compares with ... sales of $153,779,000 for the first quarter ended October 31, ... the first quarter ended October 31, 2016 to $21,323,000, or ...
(Date:12/8/2016)... , December 8, 2016 Stock-Callers.com ... the research, distribution, and marketing of pharmaceutical drug products. ... patent protection and expiration. Additionally, these firms typically have ... as a whole. Up for review this morning are: ... Pharmaceuticals Inc. (NASDAQ: SGYP ), Pernix Therapeutics ...
(Date:12/8/2016)... DES MOINES, Iowa , Dec. 8, 2016 ... STLT), a pharmaceutical company advancing technologies designed to ... the appointment of Chitra Edwin , Ph.D., ... and Compliance. Dr. Edwin will provide leadership for ... planning for regulatory approvals, preparation of regulatory submissions, ...
Breaking Medicine Technology: